Why Tyra Biosciences Is Back on Investors’ Radar

Tyra Biosciences (TYRA) has drawn fresh attention after William Blair initiated coverage highlighting its drug candidate dabogratinib, along with recent pipeline progress, the start of a Phase 2 trial, and new executive appointments that together helped spotlight the stock.

Tyra’s share price has pulled back slightly in the last week but still sits at US$29.19 after a strong 90 day share price return of 85.57%. Its 1 year total shareholder return of 138.29% and 3 year total shareholder return of 117.03% suggest momentum has recently been building rather than fading.

If you are watching how biotech headlines move stocks, it can also be useful to see what else is setting up interestingly across the market with 23 top founder-led companies.

With Tyra trading at US$29.19 and analyst targets pointing higher, along with very strong recent returns, you have to ask: is there still mispricing here, or are markets already baking in the company’s future growth?

Preferred Price-to-Book of 5.6x: Is It Justified?

Tyra Biosciences currently trades on a P/B of 5.6x, which sits below the 7.7x average for its closest peers but above the broader US Biotechs industry at 2.7x. At a last close of $29.19, that mix of cheaper than peers yet richer than the industry is what many investors will focus on.

P/B compares the company’s market value to its net assets on the balance sheet. It is often used for early stage biotechs that do not yet generate meaningful revenue or profits. With Tyra reporting no revenue and a net loss of $111.684m, earnings-based metrics such as P/E are not useful here, so book value becomes a more practical anchor.

Relative to direct peers on 7.7x, Tyra screens as good value on this measure. This indicates the market is not assigning a premium multiple even after a very strong recent share price run. However, compared to the wider US Biotechs industry on 2.7x, the 5.6x P/B points to a richer valuation that assumes more from the pipeline than the average biotech, and investors will need to judge whether that confidence is warranted.

Result: Price-to-book of 5.6x (ABOUT RIGHT)

However, there is still clear risk here, including Tyra’s US$111.684m net loss and the uncertainty that always surrounds clinical trial outcomes and timelines.

Build Your Own Tyra Biosciences Narrative

If you look at this and reach a different conclusion, or simply prefer to test the numbers yourself, you can build a personalised view in just a few minutes with Do it your way.

A great starting point for your Tyra Biosciences research is our analysis highlighting 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Tyra has caught your attention, do not stop there. Use this momentum to scan for other opportunities that fit your style before the crowd catches on.

• Target potential value standouts by checking companies on our 55 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them yet.
• Focus on resilience and sleep easier at night by reviewing businesses in the 85 resilient stocks with low risk scores that show lower overall risk scores.
• Get ahead of the market by spotting tomorrow’s possible winners early through our screener containing 23 high quality undiscovered gems with strong underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.